November 29, 2016 - By Louis Casey · 0 Comments
The stock of Cellectis SA Ads (NASDAQ:CLLS) registered a decrease of 10.4% in short interest. CLLS’s total short interest was 807,500 shares in November as published by FINRA. Its down 10.4% from 901,200 shares, reported previously. With 103,500 shares average volume, it will take short sellers 8 days to cover their CLLS’s short positions. The short interest to Cellectis SA Ads’s float is 3.34%. About 108,523 shares traded hands. Cellectis SA (ADR) (NASDAQ:CLLS) has declined 37.57% since April 26, 2016 and is downtrending. It has underperformed by 42.83% the S&P500.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The company has a market cap of $614.53 million. The Firm specializes in the research, development and commercialization of rational genome engineering technologies. It currently has negative earnings. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
More news for Cellectis SA (ADR) (NASDAQ:CLLS) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on March 25, 2015. Quotes.Wsj.com‘s article titled: “DOW JONES, A NEWS CORP COMPANY” and published on March 21, 2015 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey